ROFLUMILAST is a pharmaceutical substance that belongs to the class of selective phosphodiesterase-4 (PDE4) inhibitors. It is primarily used as an anti-inflammatory drug in the treatment of chronic obstructive pulmonary disease (COPD). The chemical name for ROFLUMILAST is 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide.
The CAS number for ROFLUMILAST is 162401-32-3. It was developed and is marketed under the brand name Daliresp by AstraZeneca. ROFLUMILAST works by inhibiting the enzyme PDE4, which is responsible for the degradation of cyclic adenosine monophosphate (cAMP) in lung cells. By inhibiting PDE4, ROFLUMILAST increases the levels of cAMP, which reduces inflammation and enhances bronchodilation in patients with COPD.
ROFLUMILAST is available in oral tablet form and is typically prescribed as a maintenance treatment for severe COPD associated with chronic bronchitis. It is not recommended for the treatment of acute exacerbations of COPD or asthma. Common side effects